hepat
c
viru
hcv
affect
estim
popul
lead
caus
chronic
liver
diseas
worldwid
sinc
hcv
therapeut
prevent
option
limit
develop
new
hcv
antivir
becom
global
health
care
concern
spur
develop
cellbas
infecti
hcv
highthroughput
screen
assay
test
abil
compound
inhibit
hcv
infect
unit
describ
method
may
use
assess
vitro
efficaci
hcv
antivir
use
cellbas
highthroughput
fluoresc
reson
energi
transfer
fret
hcv
infect
screen
assay
allow
identif
inhibitor
target
hcv
step
viral
life
cycl
basic
protocol
provid
compound
screen
hcv
infect
analysi
compound
efficaci
use
hcv
fret
assay
support
protocol
provid
propag
infecti
hcv
measur
viral
infect
keyword
hepat
c
viru
r
viral
lifecycl
r
cell
r
dimethylsulfoxid
dmso
r
fluoresc
reson
energi
transfer
fret
r
proteas
r
antivir
r
highthroughput
screen
cell
mainten
medium
see
recip
cell
mainten
medium
vv
dimethyl
sulfoxid
dmso
tissu
cultur
grade
compound
librari
hcvcc
stock
titer
see
support
protocol
fret
lysi
buffer
see
recip
prechil
c
larger
tissu
cultur
flask
clear
flatbottom
black
microtit
biocoat
tissu
cultur
plate
bd
bioscienc
ubottom
microtit
plate
plate
seal
addit
reagent
equip
grow
mammalian
cell
phelan
prepar
nongrow
cell
screen
plate
cultur
cultur
cell
larger
tissu
cultur
flask
cell
mainten
medium
cell
reach
confluenc
cell
doubl
everi
hr
condit
select
appropriates
tissu
cultur
flask
base
number
tissu
cultur
screen
plate
seed
flask
confluenc
contain
cell
suffici
tissu
cultur
plate
seed
well
clear
flatbottom
black
microtit
biocoat
tissu
cultur
plate
cell
cell
mainten
medium
incub
confluent
collagen
matrix
necessari
proper
longev
cell
cultur
presenc
dmso
collagenco
tissu
cultur
plate
eg
biocoat
bd
bioscienc
commerci
avail
coat
plate
collagen
laboratori
viabl
altern
cell
monolay
confluent
day
decant
medium
replac
cell
mainten
medium
contain
dmso
continu
incub
continu
cultur
cell
cell
mainten
medium
dmso
day
decant
medium
replac
fresh
cell
mainten
medium
dmso
everi
day
hepat
c
viru
hcv
hepatotrop
pathogen
caus
liver
diseas
includ
fibrosi
cirrhosi
steatosi
insulin
resist
iron
overload
hepatocellular
carcinoma
estim
million
peopl
chronic
infect
hcv
major
caus
liver
diseas
worldwid
repres
global
healthcar
concern
unfortun
prevent
vaccin
protect
hcv
infect
avail
ifnbas
standard
care
therapi
pegyl
plu
ribavirin
costli
poorli
toler
associ
signific
side
effect
effect
fraction
chronic
infect
individu
therefor
pathogen
discuss
within
chapter
need
develop
newgener
hcv
antiinfect
healthcar
imper
although
sever
small
molecul
target
hcv
replic
clinic
pipelin
emerg
viral
escap
mutant
indic
combin
antihcv
drug
target
multipl
aspect
infect
like
requir
success
treat
major
patient
thu
unit
aim
facilit
discoveri
hcv
antivir
describ
method
test
evalu
promis
antivir
compound
vitro
abil
screen
hcv
antivir
inhibit
aspect
infect
made
possibl
develop
first
robust
vitro
hcv
infect
model
current
protocol
microbiolog
wakita
et
al
zhong
et
al
recapitul
entir
viral
life
cycl
allow
hcv
propag
cell
cultur
unit
focus
procedur
highthroughput
antihcv
compound
screen
basic
protocol
describ
screen
compound
antihcv
activ
microtit
plate
format
use
nondivid
synchron
hepatoma
cell
allow
reproduc
hcv
infect
vitro
use
low
multipl
infect
approach
basic
protocol
describ
simpl
mixandread
fretbas
hcv
proteas
assay
use
assess
hcv
infect
determin
compound
efficaci
stock
infecti
hcv
requir
basic
screen
protocol
support
protocol
detail
prepar
necessari
hcv
stock
also
provid
support
protocol
explain
gener
infecti
hcv
vitrotranscrib
hcv
rna
support
protocol
describ
amplif
origin
hcv
stock
support
protocol
list
method
assess
infect
titer
hcv
stock
produc
togeth
protocol
encompass
sever
new
approach
compound
screen
hcv
antivir
drug
discoveri
caution
hcv
biosafeti
level
pathogen
follow
appropri
guidelin
regul
use
handl
pathogen
microorgan
see
unit
pertin
resourc
appendix
inform
note
solut
equip
come
contact
live
cell
must
steril
asept
techniqu
use
accordingli
note
cultur
incub
perform
humidifi
c
co
incub
unless
otherwis
specifi
develop
robust
cell
culturebas
hcv
infect
system
wakita
et
al
zhong
et
al
possibl
screen
hcv
inhibitor
act
stage
viral
life
cycl
eg
entri
replic
assembl
egress
spread
follow
antihcv
compound
screen
protocol
yu
et
al
accomplish
low
multipl
infect
moi
hcv
infect
approach
consist
multipl
round
infect
reinfect
adequ
reproduc
allow
z
valu
greater
achiev
use
nondivid
synchron
hepatoma
cell
specif
treatment
human
hepatoma
cell
line
dmso
induc
cell
growth
arrest
allow
nondivid
cell
maintain
stabl
cell
number
extend
period
time
sainz
chisari
importantli
nondivid
cultur
scale
microtiterpl
format
compound
librari
screen
support
highli
reproduc
hcv
infect
well
well
minim
sampletosampl
variabl
commonli
associ
cellbas
viral
assay
yu
et
al
establish
nondivid
cell
cultur
inocul
cell
culturepropag
hcv
hcvcc
low
moi
infect
allow
progress
day
presenc
absenc
test
compound
compound
typic
ad
three
time
throughout
cours
infect
day
post
infect
treatment
time
frequenc
adjust
eg
treatment
day
post
infect
howev
inhibitor
hcv
entri
effici
detect
treatment
includ
regimen
follow
infect
cultur
lyse
hcv
inhibit
assess
proteas
fret
analysi
basic
protocol
presenc
dmso
cell
continu
divid
day
post
treatment
time
cell
undergo
cellcycl
arrest
ie
g
illustr
standard
plate
layout
two
column
reserv
control
howev
compound
librari
often
provid
one
empti
column
addit
control
layout
chosen
individu
screen
campaign
need
adapt
accommod
restrict
necessari
avoid
area
prone
edg
effect
plate
one
treatment
day
store
compound
aliquot
plate
accord
storag
condit
specifi
compound
replac
test
control
compound
ubottom
compound
plate
step
expedit
transfer
compound
microtit
plate
use
multichannel
pipettor
advis
use
multichannel
pipettor
dispens
compound
care
must
taken
ensur
equal
volum
taken
dispens
inocul
well
hcvcc
inoculum
step
mock
inocul
cell
mainten
medium
alon
use
multichannel
pipettor
reagent
reservoir
contain
hcvcc
inoculum
mock
inoculum
eg
medium
alon
advis
use
multichannel
pipettor
dispens
viru
care
must
taken
ensur
equalvolum
dispens
use
aerosol
filter
pipet
tip
recommend
handl
viru
test
control
compound
concentr
dmso
concentr
incub
hcv
infectedcompound
treat
screen
plate
hr
recommend
plate
stack
within
incub
rather
laid
separ
ga
exchang
equal
among
plate
reduc
edg
effect
tradit
observ
use
microtit
plate
cellbas
screen
replac
test
compoundcontain
medium
day
chang
medium
screen
plate
remov
anoth
set
triplic
test
compound
plate
step
contain
test
compound
control
equilibr
room
temperatur
add
cell
mainten
medium
well
dilut
compound
treatment
concentr
take
correspond
hcvccinfect
screen
plate
step
incub
set
hood
sever
group
demonstr
abil
hcv
proteas
cleav
synthet
peptid
contain
enzym
natur
viral
cleavag
site
kakiuchi
et
al
optim
cleavag
sequenc
substrat
length
abil
attach
acceptor
donor
fluorogen
moieti
end
peptid
substrat
without
loss
enzymesubstr
interact
also
establish
improv
vitro
kinet
paramet
proteas
activ
made
bianchi
et
al
develop
sitederiv
demeecashl
depsipeptid
substrat
standard
amid
bond
cleavag
site
p
p
residu
replac
ester
bond
result
readili
cleav
peptid
serv
effici
fret
substrat
continu
measur
proteas
activ
cellfre
assay
use
purifi
proteas
taliani
et
al
edan
dabcyl
select
donoracceptor
pair
substrat
high
degre
spectral
overlap
fluoresc
emiss
edan
absorpt
dabcyl
result
effici
proximitydepend
quench
hcv
fret
substrat
commerci
avail
anaspec
use
success
other
monitor
hcv
subgenom
replicon
level
cell
lysat
oboyl
et
al
follow
protocol
howev
use
new
sensit
fret
substrat
fig
fret
substrat
intern
quench
peptid
fluoresc
donor
acceptor
qxl
oppos
side
proteas
cleavag
site
b
fret
proteas
assay
donor
absorb
energi
nm
emit
energi
ie
fluoresc
nm
howev
close
contact
intact
peptid
acceptor
absorb
energi
emit
donor
prevent
fluoresc
cleavag
peptid
increas
distanc
fluorophor
result
proport
fluoresc
diagram
figur
adapt
anaspec
product
inform
http
wwwanaspeccomproductsproductasp
current
protocol
microbiolog
supplement
assay
perform
higher
wavelength
excitationemiss
nm
avoid
cellular
background
fluoresc
commonli
detect
read
edan
anaspec
improv
substrat
provid
increas
fluoresc
quantum
yield
well
longer
emiss
wavelength
diminish
autofluoresc
ten
time
sensit
edansdabcylbas
assay
allow
detect
littl
pmol
hcv
proteas
sampl
plate
basic
protocol
fret
peptid
substrat
anaspec
resuspend
distribut
singleus
aliquot
upon
receipt
fret
assay
buffer
anaspec
dithiothreitol
dtt
appendix
fluoresc
micropl
reader
excit
emiss
filter
shake
platform
centrifug
microtit
plate
carrier
set
assay
program
fluoresc
micropl
reader
necessari
assay
paramet
sampl
layout
take
consider
instrumentspecif
set
remov
one
sampl
plate
c
place
sampl
plate
ice
thaw
slowli
shake
platform
shaker
hr
method
plate
thaw
prior
analysi
critic
platetopl
reproduc
thaw
ice
avoid
degrad
activ
minim
differenti
thaw
pattern
across
plate
ii
shake
plate
help
minim
differenti
thaw
pattern
iii
everi
plate
thaw
exactli
period
time
prior
assay
time
point
min
plate
thaw
complet
take
one
aliquot
fret
peptid
substrat
dtt
freezer
take
fret
assay
buffer
refriger
allow
equilibr
room
temperatur
min
sinc
discoveri
propag
hcv
vitro
hamper
infecti
clone
avail
replic
cultur
cell
howev
wakita
colleagu
clone
hcv
consensu
genotyp
genom
japanes
fulmin
hepat
patient
kato
et
al
kato
et
al
subsequ
found
produc
infecti
hcv
cell
cultur
wakita
et
al
zhong
et
al
sever
infecti
chimer
hcv
clone
produc
sinc
could
also
use
analog
clone
describ
herein
full
length
viral
consensu
sequenc
clone
puc
dna
vector
transcript
control
promot
kato
et
al
approxim
kb
length
express
ampicillin
resist
propag
dam
e
coli
select
presenc
ampicillin
purifi
dna
linear
end
hcv
clone
restrict
enzym
xbai
allow
vitro
transcript
genom
rna
precis
end
hcv
rna
electropor
cell
initi
hcv
replic
infecti
viru
product
viru
secret
medium
titer
infecti
viru
level
express
focu
form
unit
ffu
per
ml
tcid
support
protocol
cell
clone
eg
cell
zhong
et
al
typic
secret
focusform
unit
ffu
per
ml
follow
transfect
vitro
transcrib
rna
infect
hcvcc
support
protocol
cell
hepatoma
cell
isol
japanes
male
well
differenti
hepatocellular
carcinoma
nakabayashi
et
al
cell
evolv
passag
differ
laboratori
recent
screen
cell
differ
laboratori
suggest
major
cell
remain
permiss
hcvcc
infect
hcvcc
propag
protocol
describ
unit
optim
use
specif
cell
line
effect
cell
line
slight
cell
linespecif
modif
current
protocol
microbiolog
supplement
ruiz
kaper
spincolumn
chromatographi
phenol
chloroform
extract
isopropanol
precipit
chomczynski
sacchi
kingston
et
al
determin
hcvcc
infect
titer
support
protocol
linear
plasmid
dna
digest
xbai
overnight
c
accord
enzym
manufactur
protocol
digest
dna
recommend
facilit
effici
recoveri
linear
purif
linear
plasmid
templat
confirm
agaros
gel
electrophoresi
purifi
linear
plasmid
templat
sampl
volum
less
adjust
least
nucleasefre
distil
water
prior
purif
add
buffer
phenol
ph
vortex
sampl
vigor
resuspend
dna
pellet
nucleasefre
distil
water
determin
dna
concentr
spectrophotometri
incub
c
hr
rel
long
incub
proven
effect
synthesi
larg
hcv
rna
howev
optim
incub
period
depend
specif
vitro
transcript
reagent
use
need
empir
determin
remov
dna
templat
add
u
dnase
mix
well
incub
c
min
purifi
rna
use
one
follow
method
rna
purif
kit
phenolfre
total
rna
purif
kit
ribozol
plu
rna
purif
kit
amresco
b
lithium
chlorid
precipit
diazruiz
kaper
c
spincolumn
chromatographi
phenol
chloroform
extract
isopropanol
precipit
chomczynski
sacchi
kingston
et
al
purif
method
includ
limit
method
method
particular
benefit
conveni
effect
way
recov
rna
author
routin
employ
phenol
chloroform
extract
isopropanol
precipit
determin
rna
concentr
use
spectrophotomet
gallagh
desjardin
prepar
cell
time
point
day
prior
transfect
seed
cell
tissu
cultur
flask
respect
cell
mainten
medium
incub
overnight
transfer
cell
ml
centrifug
tube
bring
volum
ml
prechil
c
serumfre
dmem
optimem
pellet
cell
min
g
c
refriger
centrifug
aspir
medium
cell
pellet
resuspend
cell
ml
prechil
serumfre
dmem
optimem
pellet
cell
min
g
c
refriger
centrifug
repeat
addit
two
time
remov
serumassoci
protein
third
wash
remov
supernat
resuspend
cell
pellet
prechil
serumfre
dmem
optimem
concentr
cellsml
viru
product
kinet
vari
follow
transfect
depend
cell
lineclon
hcv
construct
use
well
method
transfect
report
use
chimer
viru
construct
indic
optim
viral
titer
achiev
day
post
transfect
other
use
viral
clone
indic
maxim
titer
achiev
day
post
transfect
zhong
et
al
clarifi
condit
medium
contain
hcvcc
centrifug
min
g
c
remov
cell
debri
filter
supernat
cellulos
acet
filter
may
excess
cell
cultur
medium
day
post
transfect
effici
electropor
often
result
notic
cell
death
follow
filtrat
dispens
cultur
fluid
aliquot
store
indefinit
c
research
report
store
hcvcc
c
without
rapid
loss
infect
howev
author
alway
store
hcvcc
stock
c
storag
presenc
fetal
bovin
serum
contain
medium
collect
promot
viral
stabil
respect
repeat
freezethaw
cycl
howev
viru
propag
absenc
serum
purifi
away
serum
protein
less
stabl
lose
infect
repeat
freezethaw
cycl
cell
infect
hcvcc
use
propag
infecti
viru
manner
similar
propag
methodolog
util
virus
depend
cell
line
hcv
viral
clone
use
maxim
titer
obtain
day
follow
inocul
monolay
suspens
cultur
moi
ffucel
advantag
methodolog
gener
hcvcc
vitrotranscrib
rna
support
protocol
eas
procedur
ii
reduc
time
frame
iii
abil
gener
larg
volum
stock
hcvcc
rna
virus
accumul
mutat
everi
time
genom
replic
imposs
gener
clonal
stock
hcvcc
recommend
viru
passag
multipl
time
transfect
order
limit
select
specif
adapt
mutat
onepassag
protocol
detail
unit
optim
gener
ml
infecti
hcvcc
per
harvest
day
cell
titer
rang
ffuml
howev
slight
adjust
cell
confluenc
harvest
time
may
necessari
grow
differ
viral
clonesmut
use
cell
clone
exhibit
profound
hcvccinduc
cpe
cell
case
optim
viru
yield
cell
maintain
subconflu
throughout
viral
propag
process
decant
cultur
medium
infect
posttransfect
gener
hcvcc
moi
ffucel
volum
ml
cell
mainten
medium
assum
cell
ffu
hcvcc
need
inocul
evid
cytopath
effect
observ
cell
usual
day
post
infect
harvest
cultur
medium
daili
transfer
condit
medium
plastic
centrifug
tube
determin
hcvcc
infect
titer
see
support
protocol
viral
infect
assay
sever
differ
techniqu
cytolyt
virus
like
herp
virus
coronavirus
commonli
use
techniqu
plaqu
assay
cultur
cell
monolay
absenc
presenc
inert
overlay
methylcellulos
agaros
cooper
viral
infect
titer
express
plaqueform
unit
pfu
ml
calcul
base
number
discret
plaqu
form
cell
monolay
dilut
inoculum
inoculum
volum
hcvcc
noncytolyt
form
plaqu
monolay
form
small
foci
hcv
proteinposit
cell
visual
immunostain
fix
infect
monolay
count
calcul
hcv
infect
titer
express
focusform
unit
ffu
ml
reduc
satellit
foci
due
secondari
spread
assay
period
protocol
includ
addit
methylcellulos
overlay
methodolog
detail
unit
describ
horseradish
peroxidasebas
stain
procedur
author
determin
user
friendli
cost
effect
howev
use
fluorescentlylabel
secondari
antibodi
also
describ
zhong
et
al
cell
japan
health
scienc
research
resourc
bank
cat
cell
mainten
medium
see
recip
hcvcc
test
sampl
see
protocol
cell
mainten
medium
wv
methylcellulos
see
recip
pfa
fixat
buffer
see
recip
dulbecco
phosphat
buffer
salin
dpb
without
calcium
magnesium
see
recip
appendix
prepar
tissueculturegrad
h
omit
ca
mg
dpb
without
ca
mg
contain
hydrogen
peroxid
prepar
immedi
use
block
buffer
see
recip
hcvspecif
primari
antibodi
ab
eg
human
antihcv
antibodi
law
et
al
mous
antihcv
antibodi
mous
antihcv
core
affin
bioreag
bind
buffer
see
recip
appropri
hrpconjug
secondari
antibodi
ab
dakocytom
envis
systemhrp
label
readytous
antimous
antibodi
primari
ab
rais
mous
goat
antihuman
hrpconjug
antibodi
pierc
primari
ab
rais
human
aec
peroxidas
substrat
solut
bd
bioscienc
vv
block
endogen
peroxidas
present
hepatocyt
add
hydrogen
peroxid
dpb
well
incub
min
room
temperatur
decant
peroxid
wash
cell
three
time
dpb
add
block
buffer
well
incub
hr
room
temperatur
add
primari
ab
dilut
bind
buffer
well
see
tabl
antibodi
dilut
list
tabl
academ
avail
antibodi
target
hcv
glycoprotein
law
et
al
viral
protein
addit
third
commerci
avail
antibodi
target
hcv
core
protein
also
list
three
antibodi
equal
suitabl
hrpbase
immunocytochem
procedur
describ
within
unit
use
averag
number
foci
triplic
well
calcul
titer
ffuml
use
follow
formula
titer
ffuml
foci
number
factor
viru
prepar
plate
ml
altern
express
infect
titer
tissu
cultur
infecti
dose
tcid
select
cultur
well
express
least
one
hcvposit
cell
determin
tcid
accord
method
reed
muench
reed
muench
cat
ml
water
steril
bottl
contain
stir
bar
stir
c
methylcellulos
partial
goe
solut
hr
heat
methylcellulos
dissolv
cold
solut
steril
autoclav
allow
solut
return
room
temperatur
methylcellulos
solidifi
shake
vigor
break
clump
transfer
c
overnight
possibl
stir
methylcellulos
gradual
go
solut
methylcellulos
overlay
add
part
methylcellulos
stock
solut
part
cell
mainten
medium
mix
well
store
c
dark
g
paraformaldehyd
pfa
ml
dulbecco
phosphatebuff
salin
dpb
without
calcium
magnesium
see
recip
appendix
prepar
tissueculturegrad
h
omit
ca
mg
adjust
ph
n
naoh
pfa
go
solut
ph
aid
dissolut
heat
solut
fume
hood
let
solut
rise
c
bring
ml
total
volum
dpb
without
cacl
mgcl
filter
steril
wrap
aluminum
foil
store
year
c
mm
ph
appendix
mm
sodium
chlorid
mm
magnesium
chlorid
aliquot
store
year
c
hepat
c
viru
hcv
hepatotrop
envelop
positivestrand
rna
viru
primari
caus
agent
liver
diseas
worldwid
current
hcv
affect
million
individu
global
caus
signific
liver
diseas
includ
cirrhosi
hepatocellular
carcinoma
hcc
chronic
infect
individu
alter
seeff
fact
unit
state
hcvrelat
hcc
account
hcc
case
liver
transplant
perform
annual
hcv
classifi
famili
flavivirida
base
conserv
viral
rnadepend
rna
polymeras
genom
organ
kb
rna
genom
flank
highli
structur
untransl
region
encod
singl
open
read
frame
translat
via
viral
intern
ribosom
entri
site
viral
polyprotein
viral
polyprotein
coand
posttransl
cleav
structur
nonstructur
ns
protein
host
viral
proteas
ns
viral
protein
assembl
cellular
membran
endoplasm
reticulum
mediat
format
viral
rna
replic
complex
also
known
membran
web
neg
strand
rna
synthesi
occur
gosert
et
al
negativestrand
rna
provid
templat
amplif
positivestrand
genom
rna
subsequ
encapsid
viral
nucleocapsid
protein
ie
core
direct
cellular
lipoprotein
secretori
pathway
progeni
virion
matur
becom
lipid
prior
exit
cell
sinc
discoveri
effect
treatment
option
hcv
interferon
treatment
combin
ribavirin
glue
et
al
unfortun
therapi
wide
spectrum
toxic
side
effect
effect
subset
patient
number
hcv
patient
requir
treatment
expect
significantli
increas
next
decad
william
obviou
immedi
need
new
effect
hcv
antivir
result
highthroughputscreen
ht
assay
util
recent
develop
infecti
hcv
cell
cultur
system
wakita
et
al
zhong
et
al
mean
identifi
new
antihcv
compound
target
step
hcv
life
cycl
need
unit
describ
uniqu
hcv
ht
cellbas
fluoresc
reson
energi
transfer
fret
assay
antivir
compound
screen
yu
et
al
combin
use
infecti
hcvcc
nondivid
hepatoma
cell
cultur
sainz
chisari
choi
et
al
sensit
fretbas
readout
endogen
virallyencod
proteas
assay
offer
sever
distinct
advantag
convent
hcv
antivir
compound
screen
assay
first
tradit
viral
ht
assay
typic
aim
achiev
synchron
singlecycl
round
viral
replic
use
high
multipl
infect
moi
approach
result
bias
select
inhibitor
target
viral
entri
replic
compound
inhibit
later
viral
infect
process
matur
egress
subsequ
celltocel
spread
avoid
predisposit
identifi
inhibitor
aspect
viral
life
cycl
hcv
ht
assay
describ
herein
base
lowmoi
infect
multipl
round
hcv
infect
spread
viru
throughout
cultur
occur
inhibitor
target
step
viral
life
cycl
success
identifi
secondli
accommod
long
infect
hcv
ht
assay
make
use
nondivid
synchron
hepatoma
cell
cultur
allow
highli
reproduc
robust
hcvcc
infect
extend
period
time
virtual
elimin
welltowel
cell
culturerel
variabl
often
plagu
cellbas
ht
strategi
addit
readyforus
cultur
easili
maintain
inher
toler
common
compound
librari
diluent
dimethylsulfoxid
dmso
averag
research
also
advantag
describ
hcv
fret
assay
perform
standard
infecti
hcv
clone
ie
special
report
need
engin
viral
genom
make
use
sensit
commerci
avail
intern
quench
peptid
substrat
cell
cultur
hcvrelat
cell
cultur
use
lowpassag
cell
least
usag
cell
within
defin
hcvpermiss
cell
passag
window
current
protocol
microbiolog
supplement
recommend
addit
imper
cell
mycoplasma
free
greater
viabl
use
hcv
infect
affect
variabl
cultur
cell
dmso
induc
cell
growth
arrest
involv
addit
consider
first
method
proven
success
numer
distinct
cell
line
recommend
cell
line
test
individu
ensur
cell
behav
expect
eg
cell
growth
cessat
liverspecif
gene
express
enhanc
occur
approxim
day
post
dmso
treatment
one
potenti
problem
dmso
treatment
excess
dmso
result
cell
death
cytotox
prepar
cell
mainten
medium
vv
dmso
accur
measur
volum
ensur
final
dmso
concentr
use
tissueculturegrad
dmso
sigma
recommend
anoth
potenti
problem
overgrowth
cell
presenc
dmso
happen
cell
mainten
medium
dmso
initi
ad
cultur
late
cell
alreadi
confluent
overconflu
rather
confluent
judgement
regard
add
dmsocontain
medium
subject
determin
empir
begin
largescal
experi
dmsotreat
cultur
lastli
incub
period
medium
must
chang
everi
day
cell
incub
presenc
dmso
extrem
metabol
activ
thu
util
nutrient
rate
significantli
faster
activ
divid
counterpart
medium
ph
quickli
becom
acid
nutrient
rapidli
exhaust
particularli
day
dmso
treatment
medium
chang
everi
day
therefor
necessari
hcv
infect
ensur
reproduc
throughout
singl
librari
screen
effort
hcvcc
stock
suffici
complet
entir
screen
produc
detail
infect
kinet
establish
prior
screen
subsequ
viru
storag
handl
techniqu
also
standard
compound
screen
unit
describ
approach
accommod
unstabl
compound
must
kept
frozen
minimum
freezethaw
cycl
howev
handl
differ
compound
librari
determin
accord
stabil
properti
compound
test
eg
may
possibl
use
deepwel
microtit
plate
predilut
drug
suffici
medium
medium
chang
store
c
infect
perform
screen
standard
posit
neg
control
must
includ
individu
screen
plate
intern
control
result
compar
plate
posit
control
could
known
potent
hcv
inhibitor
ifn
neg
control
includ
diluent
treatment
hcv
fret
assay
simpl
mixandread
fluorescencebas
assay
measur
hcv
infect
function
proteas
activ
cellbas
system
like
ht
assay
howev
critic
care
consid
paramet
lysi
reagent
substrat
activ
statist
valid
assay
data
interpret
lysi
buffer
complet
lysi
cell
need
proper
quantif
proteas
activ
standard
grow
monolay
effici
lyse
tradit
lysi
buffer
includ
provid
manufactur
substrat
anaspec
lysi
cultur
requir
stringent
condit
due
tightli
pack
morpholog
individu
lysi
buffer
empir
test
determin
fret
lysi
buffer
describ
unit
see
reagent
solut
allow
suffici
cell
cultur
lysi
without
reduc
proteas
activ
yu
et
al
addit
recommend
screen
plate
frozen
fret
analysi
cell
undergo
one
freezethaw
cycl
fret
lysi
buffer
substrat
fret
peptid
substrat
anaspec
chosen
high
sensit
howev
fret
peptid
substrat
contain
appropri
hcv
cleavag
site
would
suitabl
long
final
signaltonois
ratio
accept
particular
import
develop
fluorescencebas
assay
typic
lower
signaltobackground
ratio
commonli
ht
assay
zhang
et
al
thu
altern
substrat
util
advis
optim
signaltobackground
ratio
test
multipl
lysi
buffer
readout
paramet
appropri
panel
posit
neg
control
prior
perform
compound
screen
campaign
assay
hepat
c
antivir
compound
screen
supplement
current
protocol
microbiolog
import
fluoresc
tag
peptid
substrat
proper
storag
handl
fluoresc
tag
peptid
substrat
light
temperatur
sensit
care
taken
reduc
exposur
substrat
light
avoid
repeat
freezethaw
cycl
avoid
issu
control
lottolot
substrat
variabl
recommend
feasibl
obtain
bulk
quantiti
particular
peptid
substrat
lot
immedi
aliquot
ice
individu
singleus
tube
kept
c
longterm
storag
fret
peptid
substrat
anaspec
suffici
test
entir
microtit
sampl
plate
aliquot
volum
adjust
base
individu
compound
screen
need
statist
valid
hcv
fret
assay
critic
ht
reproduc
consist
assay
perform
z
factor
valu
measur
qualiti
assay
assess
dynam
rang
well
variat
within
assay
measur
distanc
standard
deviat
posit
signal
neg
nois
control
valu
also
assess
welltowel
variabl
noiseerror
associ
assay
ht
consid
accur
z
valu
greater
necessari
follow
procedur
outlin
unit
hcv
fret
describ
routin
exhibit
z
factor
greater
yu
et
al
howev
empir
determin
userlaboratori
data
interpret
success
compound
screen
assay
lie
abil
assay
distinguish
hit
nonhit
thu
import
calcul
assay
hit
ratio
determin
appropri
hit
window
identifi
candid
antihcv
compound
describ
zhang
et
al
biolog
perspect
advis
follow
compound
reproduc
inhibit
hcv
relat
hit
zone
hit
zone
identifi
unmanag
number
hit
stringent
hit
window
eg
establish
likewis
compound
identifi
use
hit
zone
hit
window
increas
eg
accept
test
compound
potenti
inhibitor
hcvcc
vitrotranscrib
rna
qualiti
abil
effici
produc
infecti
hcvcc
transfect
vitrotranscrib
hcv
rna
depend
presenc
suffici
quantiti
fulllength
hcv
rna
genom
express
vector
contain
promot
suitabl
vitro
rna
transcript
kb
rna
genom
optim
may
necessari
optim
synthesi
larg
hcv
rna
transcript
even
use
commerci
avail
transcript
kit
accord
manufactur
recommend
highli
recommend
vitrotranscrib
rna
visual
gel
electrophoresi
assess
rna
qualiti
describ
brown
et
al
presenc
predomin
smear
rna
differ
size
rather
predomin
singl
band
slight
smear
incomplet
product
indic
incomplet
transcript
degrad
neg
impact
intracellular
hcv
rna
replic
follow
transfect
addit
rnase
inhibitor
optim
transcript
reaction
incub
period
help
ensur
rna
stock
contain
high
percent
intact
hcv
rna
genom
rna
longer
genom
length
observ
may
indic
complet
linear
templat
dna
thu
get
continu
rna
synthesi
around
intact
plasmid
resolv
either
redigest
templat
incorpor
step
linear
templat
dna
separ
agaros
gel
purif
final
contamin
protein
residu
phenol
chloroform
ethanol
may
reduc
transfect
effici
spectrophotometr
analysi
vitro
transcrib
rna
recommend
confirm
rna
puriti
purif
includ
option
proteinas
k
treatment
step
perform
necessari
obtain
better
rna
puriti
transfect
origin
report
describ
gener
hcvcc
vitro
transcrib
rna
util
electropor
transfect
cell
wakita
et
al
zhong
et
al
differ
cell
line
may
respond
optim
slightli
differ
electropor
condit
paramet
describ
repres
reason
start
point
optim
addit
choic
transfect
method
theoret
limit
electropor
methodolog
cation
lipidmedi
transfect
use
lipofectamin
invitrogen
also
use
compar
efficaci
zhong
et
al
thu
rnasefre
transfect
protocol
suitabl
long
intact
rna
deliv
effect
target
cell
effici
least
supplement
case
advis
first
ensur
least
determin
parallel
transfect
protocol
effect
use
plasmid
vector
encod
report
gene
gfp
hcv
replic
failur
produc
detect
level
infecti
hcvcc
may
also
due
inadequ
intracellular
replic
transfect
vitrotranscrib
hcv
rna
although
major
cell
permiss
hcvcc
infect
support
robust
hcv
replicon
rna
replic
specif
laboratori
cell
line
may
support
initi
hcv
rna
replic
effici
assess
intracellular
hcv
rna
replic
follow
transfect
quantit
hcv
rna
quantit
realtim
polymeras
chain
reaction
qrtpcr
perform
describ
likewis
hcv
protein
level
indic
effici
rna
replic
determin
immunostain
describ
support
protocol
cell
major
import
gener
hightit
hcvcc
stock
state
cell
propag
optim
cellular
condit
hcvcc
grow
titer
ffuml
howev
overconflu
mycoplasma
contamin
chang
state
host
cell
neg
impact
hcv
rna
replic
de
novo
viru
product
pietschmann
et
al
windisch
et
al
nelson
tang
sainz
chisari
thu
critic
use
cell
maintain
healthi
growth
state
allow
becom
overconflu
time
transfect
infect
point
thereaft
moreov
longterm
passag
cell
permiss
hcvcc
infect
fluctuat
corcoran
et
al
unpub
observ
henc
particularli
ensur
reproduc
throughout
largescal
hcv
screen
effort
recommend
cell
passag
monitor
cell
cultur
limit
number
passag
ie
split
time
cell
discard
equival
frozen
aliquot
thaw
continu
use
obvious
requir
cell
use
initi
expand
larg
number
parallel
aliquot
frozen
futur
use
lastli
mycoplasma
contamin
avoid
cell
line
treat
determin
mycoplasma
posit
see
appendix
although
hcv
consid
noncytolyt
viru
hcvcc
infect
cell
result
detect
cytopath
effect
cpe
character
slow
cell
growth
appear
round
sometim
float
cell
degre
cpe
observ
vari
among
differ
cell
line
onset
cpe
usual
coincid
maxim
titer
product
harvest
viru
initi
onset
hcvinduc
cpe
recommend
titer
achiev
method
describ
unit
suboptim
specif
downstream
purpos
higher
titer
obtain
concentr
viral
stock
use
centrifug
concentr
amicon
centrifug
filter
unit
millipor
harvest
serumfre
medium
viru
concentr
least
without
loss
infect
cell
cultureadapt
mutat
mention
support
protocol
propag
rna
virus
mutat
incorpor
viral
genom
everi
time
replic
due
intrins
error
rate
lack
proofread
function
viral
rnadepend
rna
polymeras
henc
continu
passag
cell
cultur
select
specif
cellcultur
adapt
mutant
occur
zhong
et
al
mutat
confer
advantag
viral
growth
cell
cultur
randomli
occur
time
infect
signific
shift
viru
popul
whole
usual
requir
sever
week
continu
viru
select
occur
thu
hcvcc
propag
method
describ
support
protocol
typic
result
emergenceselect
specif
cellcultur
mutat
bulk
sequenc
viru
present
medium
collect
day
post
transfect
day
post
subsequ
infect
indic
detect
select
cell
cultur
mutat
past
viru
stock
prepar
howev
bulk
sequenc
empir
confirm
conclus
way
whether
adapt
mutat
select
within
specif
viru
stock
hcv
infect
titer
assay
describ
support
protocol
base
standard
titer
protocol
success
util
numer
virus
condit
howev
hcvspecif
paramet
note
abnorm
andor
difficult
count
hcv
foci
although
noncytolyt
hcv
form
discret
foci
monolay
ideal
hr
postinfect
cell
fix
stain
hcv
protein
posit
foci
consist
group
cell
howev
sometim
individu
foci
readili
distinguish
due
unexpect
differ
size
assay
hepat
c
antivir
compound
screen
supplement
current
protocol
microbiolog
shape
foci
although
foci
size
vari
depend
specif
cell
line
use
titer
often
case
simpl
adjust
made
optim
foci
format
first
help
includ
simpl
overlay
minim
secondari
spread
give
rise
satellit
foci
thu
addit
wv
methylcellulos
recommend
ensur
format
countabl
discret
hcv
foci
addit
foci
larg
hr
postinfect
cell
fix
stain
earlier
eg
hr
postinfect
contrast
foci
small
reliabl
count
may
result
cell
overconflu
time
infect
suboptim
media
condit
use
highpassag
cell
contamin
mycoplasma
incub
co
level
exceed
inconsist
suboptim
stain
immunostain
methodolog
issu
antibodi
specif
cell
permeabl
background
may
aris
protocol
describ
herein
use
antibodi
list
provid
tabl
design
ensur
maximum
stain
visual
hcv
foci
inconsist
suboptim
stain
encount
reagent
first
check
altern
standard
chang
antibodi
dilut
incub
period
incub
temperatur
test
lastli
addit
permeabil
step
consist
singl
wash
icecold
methanol
vv
incorpor
support
protocol
step
hcvcc
fret
assay
describ
herein
use
effect
procedur
test
efficaci
potenti
hcv
antivir
aspect
viral
life
cycl
use
nongrow
cell
cultur
provid
uniqu
cell
cultur
environ
test
efficaci
test
compound
hcv
impart
advantag
virtual
elimin
welltowel
variabl
routin
encount
cellbas
compound
screen
assay
use
activ
divid
cell
cultur
earli
day
post
incub
dmso
cell
enter
growth
arrest
soon
thereaft
form
tightli
pack
monolay
monoand
binucl
cell
display
typic
pavementlik
cytolog
featur
primari
hepatocyt
previous
describ
yu
et
al
cell
support
robust
hcvcc
infect
therefor
follow
day
infect
hcv
proteas
activ
measur
fret
fluoresc
yield
maxim
rfu
valu
untreat
noisetobackground
ratio
sampl
treat
compound
inhibit
hcv
step
viral
life
cycl
eg
entri
uncoat
translat
replic
assembl
matur
egress
yield
rfu
valu
significantli
untreat
hcvinfect
control
well
exampl
potent
inhibitor
hcv
infect
reduc
fret
rfu
valu
compar
untreat
hcvinfect
control
sampl
uncommon
see
variat
rfu
valu
experi
experi
work
differ
substrat
lot
see
critic
paramet
substrat
howev
inhibit
appropri
calcul
rel
proper
control
percent
reduct
compar
experi
experi
gener
hcvcc
cell
either
transfect
vitrotranscrib
hcv
rna
support
protocol
infect
cell
hcvcc
support
protocol
yield
titer
ffuml
howev
due
variat
inher
hcvcc
infect
observ
due
part
cell
linesclon
util
time
post
transfect
post
infect
yield
maxim
titer
vari
nonetheless
follow
protocol
describ
within
unit
maxim
titer
cell
achiev
day
post
transfect
day
post
infect
hcvcc
gener
hcv
infect
titer
assay
support
protocol
use
determin
viral
titer
express
ffuml
assay
yield
discret
hcv
foci
consist
hcv
proteinposit
cell
plan
purpos
durat
individu
step
protocol
detail
tabl
summar
fret
assay
describ
unit
basic
protocol
take
sever
week
complet
howev
assay
divid
manag
subprocedur
stop
point
along
way
afford
effici
execut
entir
assay
start
finish
compound
librari
screen
endeavor
proper
plan
prior
begin
assay
advis
ensur
need
reagentscompound
avail
appropri
dilut
current
protocol
microbiolog
supplement
foci
count
titer
analysi
hr
support
protocol
step
correct
time
mandatori
step
prepar
cell
infect
occur
appropri
interv
throughout
assay
end
design
strateg
plan
advanc
initi
assay
prevent
unanticip
error
delay
fret
assay
divid
two
basic
protocol
requir
total
day
basic
protocol
hr
basic
protocol
complet
therefor
procedur
complet
either
tandem
altern
exampl
step
end
basic
protocol
repres
stop
point
sampl
plate
store
indefinit
thu
author
advis
basic
protocol
perform
suffici
number
sampl
plate
fret
analysi
accumul
ensur
consist
fret
result
assay
plate
fluorescencerel
procedur
perform
togeth
cours
day
rather
stagger
across
sever
week
addit
advis
prepar
cell
cultur
plate
stagger
manag
number
plate
handl
one
time
sinc
cell
must
incub
week
ie
day
presenc
dmso
batch
plate
seed
weekli
thu
reduc
number
plate
treat
infect
one
time
aforement
suggest
howev
depend
number
compound
test
liquid
handl
equip
avail
assay
hepat
c
antivir
compound
screen
supplement
current
protocol
microbiolog
addit
fret
assay
describ
basic
protocol
support
protocol
detail
procedur
gener
hcvcc
determin
infect
titer
gener
hcvcc
accomplish
transfect
cell
vitrotranscrib
hcv
rna
support
protocol
infect
cell
hcvcc
support
protocol
requir
day
day
respect
hcvcc
gener
infect
titer
analysi
perform
support
protocol
within
day
focicount
titeranalysi
time
vari
depend
method
detect
hrp
versu
immunofluoresc
number
well
count
